

THE REPUBLIC OF CYPRUS

Department of Registrar of Companies and Official Receiver

**ΚΥΠΡΙΑΚΟ ΓΡΑΦΕΙΟ ΔΙΠΛΩΜΑΤΩΝ
ΕΥΡΕΣΙΤΕΧΝΙΑΣ
THE PATENT OFFICE OF CYPRUS**

**ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ
PUBLICATION NUMBER**

CY1396

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ
ΓΡΑΦΕΙΟΥ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
ΗΝΩΜΕΝΟΥ ΒΑΣΙΛΕΙΟΥ
UK PATENT OFFICE
PUBLICATION NUMBER

GB2094302

Το έγγραφο που παρουσιάζεται πιο κάτω καταχωρήθηκε στο «Γραφείο Διπλωμάτων Ευρεσιτεχνίας» στην Αγγλία σύμφωνα με το Νόμο Κεφ. 266 πριν την 1^η Απριλίου 1998. Δημοσίευση έγινε μετέπειτα από το Γραφείο Διπλωμάτων Ευρεσιτεχνίας του Ηνωμένου Βασιλείου μόνο στην Αγγλική γλώσσα.

**The document provided hereafter was filed at "The Patent Office"
in England under the law CAP.266 before the 1st of April 1998.
It was published afterwards by the UK patent office only in English.**

(12) UK Patent Application (19) GB (11) 2 094 302 A

(21) Application No **8205989**

(22) Date of filing
2 Mar 1982

(30) Priority data

(31) **1443/81**

(32) **4 Mar 1981**

(33) **Switzerland (CH)**

(43) Application published
15 Sep 1982

(51) **INT CL³ C07D 413/10**
A61K 31/535

(52) Domestic classification
C2C 1562 1590 215
21X 220 226 22Y 246
250 252 255 25Y 281
28X 29X 29Y 305 30Y
311 313 314 315 31Y
321 326 32Y 338 342
34Y 351 352 355 35Y
364 365 366 367 36Y
386 387 388 401 40Y
43X 440 449 503 509
50Y 601 620 623 624
625 628 62X 62Y 635
658 660 662 665 666
669 675 694 697 761
765 802 80Y AA KS MD
TN UJ UL

(56) Documents cited
GB 1383906
DE 2207517

(58) Field of search
C2C


(71) Applicant
Ciba Geigy AG
4002 Basle
Switzerland

(72) Inventor
Richard Goschke

(74) Agents
Ciba-Geigy (UK) Limited
Thomas Sharman
Patent Dept
Tenax Road
Trafford Park
Manchester M17 1WT

(54) **Pyridazinones**

(57) Compounds of formula (I)



(wherein R is halogen atom or amino, acetamido, methyl, cyano, hydroxy, methoxy or trifluoromethyl group), the tautomeric forms thereof, and acid addition salts of the compound in which R represents amino have antithrombotic activity.

GB 2 094 302 A


SPECIFICATION

Pyridazinones processes for producing them pharmaceutical preparations containing these compounds and the use thereof

5 The present invention relates to novel pyridazinones, especially to 4,5-dihydro-3(2H)-pyridazinones, to the production thereof, to pharmaceutical preparations which contain these novel compounds, and to their use.

German Offenlegungsschrift No. 2,207,517 has as subject matter, inter alia, 6-phenyl-4,5-dihydro-3(2H)-pyridazinones which are substituted in the p-position in the phenyl group by a heterocycle, and which exhibit antihypertensive activity.

It has now been found that the novel compounds of the general formula I



wherein R is a halogen atom, or the amino, acetylamino, methyl, cyano, hydroxyl, methoxy or trifluoromethyl group, and the tautomeric forms thereof, surprisingly have a marked antithrombotic action.


25 Halogen atoms are in particular chlorine or bromine atoms, but can also be fluorine or iodine atoms.

The compounds of the formula I have valuable pharmacological properties. They thus exhibit for example a pronounced antithrombotic action. This can be demonstrated for example on the guinea pig by virtue of the suppression of thrombocytopenia after induction by means of ADP (Thromboembolism, Edited by J.R. Mitchell and J.G. Doment, Academic Press (1977), p. 36) in 30 the dose range of about 30 to 300 mg/kg p.o., on the basis of the Forssman reaction (Thrombosis, Haemostasis 42, 100 (1979)) in the dose range of about 100 to 300 mg/kg p.o., and on the basis of the suppression of the thrombosis forming on a cotton thread in an extracorporeal shunt on the rat (method analogous to Brit. J. Pharmacol., 73, 219 P (1981) in 35 the dose range of about 5 to 50 mg/kg p.o., as well as by virtue of the suppression of the platelet aggregation, induced ex vivo by collagen or arachidonic acid, after prior peroral administration of the active substance in doses of 50 to 300 mg/kg. The compounds of the general formula I are accordingly suitable in particular for the treatment of thrombotic diseases, and can be used as active ingredients in antithrombotic pharmaceutical preparations.

40 Of particular interest in this invention are compounds in which R is a chlorine or bromine atom. To be mentioned especially is 6-(4-morpholino-3-chlorophenyl)-4,5-dihydro-3(2H)-pyridazinone. Also of special interest are compounds of the formula I in which R is an amino, acetylamino or cyano group. Furthermore, mention is made particularly of 6-(3-amino-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone, 6-(3-acetamino-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone and 6-(3-cyano-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazi- 45 none.

The novel pyridazinones of the formula I are produced by methods known per se.


The novel compounds of the formula I can thus be obtained by reacting a ketocarboxylic acid of the formula II




or a reactive derivative of such a ketocarboxylic acid, with hydrazine. There is preferably used 60 hydrazine hydrate in hydrate form, which when used in excess can also simultaneously serve as solvent. It is however, more advantageous to add an additional solvent. Suitable inert solvents are preferably alcohols, for example: methanol, ethanol, isopropanol, n-butanol, isoamyl alcohol, glycols and ethers thereof, such as ethylene glycol, diethylene glycol, ethylene glycol monomethyl ether or -monoethyl ether (methyl glycol or ethyl glycol), also ethers, especially water- 65 soluble ethers, such as tetrahydrofuran, dioxane or ethylene glycol dimethyl ether (diglymes);

and also water, as well as mixtures of these solvents with one another, particularly mixtures with water, for example aqueous ethanol. The reaction temperatures are advantageously between about 20 and about 200°C, preferably between 60 and 80°C.

Suitable reactive derivatives of the ketocarboxylic acid of the formula II are for example the esters, in particular lower alkyl esters, such as methyl or ethyl ester. It is also possible to use the acid amides and acid halides of acids of the formula II, especially the acid chlorides or acid bromides. Further suitable reactive derivatives of the carboxylic acid of the formula II can be formed in situ during the reaction. These include for example the hydrazones of the formula $R_1-C(=N-NH_2)-CH_2-VH_2-COOH$, the hydrazones of the formula $R_1-CO-CH_2-CH_2-CO-NH-NH_2$ and the hydrazones of the hydrazides of the formula




wherein R_1 is the radical



The starting materials formed in situ are produced from the ketocarboxylic acids of the formula II, and are not isolated from the reaction mixture but further reacted to the compounds of the formula I.

The compounds of the formula I can also be obtained by reacting compounds of the formula III



wherein R has the meaning defined under the formula I, and Y is a group detachable together with hydrogen, with morpholine. The employed morpholine is advantageously used as a free base in excess; it can however also be used in the form of an acid addition salt, for example as a hydrohalide, such as hydrochloride.

With use of only a slight excess of morpholine as a free base, or with use of the morpholine as an acid addition salt, it is advantageous to additionally add a stoichiometrically equivalent amount of for example a tertiary alkylamine, such as triethylamine or N-ethyl-diisopropylamine.


The described reaction of compounds of the formula III with morpholine is performed optionally in the presence of a solvent, preferably an aprotic solvent. Examples of solvents preferably used are ethers, for example diethyl ether and tetrahydrofuran, especially aliphatic ketones and esters, such as acetone, methyl ethyl ketone and ethyl acetate, aromatic hydrocarbons, for example benzene, toluene or xylene, as well as acetonitrile. The reaction is particularly preferably carried out in diethyl ether or in acetonitrile.

The reactions can be performed at a temperature of between 0 and 150°C, preferably however between room temperature and the reflux temperature of the reaction mixture.

A group Y detachable together with hydrogen is for example in particular a free or preferably etherified mercapto group, also an optionally reactive, functionally modified hydroxyl group or the nitroamino group. An etherified mercapto group is especially a mercapto group etherified by an unsubstituted or substituted hydrocarbon, particularly one of aliphatic character. It is especially lower alkylthio, for example methylthio, ethylthio or butylthio, or phenyl-lower-alkylthio, for example phenylthio or benzylthio. An optionally reactive, functionally modified hydroxyl group is a free hydroxyl group or, for example, a corresponding esterified hydroxyl group. This is for example halogen, such as chlorine or bromine, or lower alkylsulfonyloxy, for example methanesulfonyloxy.

As a group detachable together with hydrogen, Y is preferably a halogen atom, for example chlorine or bromine.


Compounds of the general formula I can also be produced by reacting a compound of the formula IV



5

10 with a diethyl ether derivative of the formula V

10



15

wherein X is a group detachable together with hydrogen.

20 The reaction of a compound of the formula IV with a compound of the formula V is performed preferably in the presence of an organic base, for example a tertiary alkylamine, such as triethylamine or N-ethyl-diisopropylamine.

20

The described reaction of compounds of the formula IV with a compound of the formula V is performed optionally in the presence of a solvent, preferably a polar solvent, for example dimethylformamide.

25 The reactions can be carried out at a temperature of between 0 and 200°C, preferably however between room temperature and the reflux temperature of the reaction mixture.


25

A group X detachable together with hydrogen has already been defined above under the formula III for the symbol Y.

30 As a group detachable together with hydrogen, X is preferably a halogen atom, for example chlorine or bromine.

30

According to a further process, compounds of the formula I wherein R is a halogen atom or the cyano group can be produced by heating a compound of the formula VI



35

40 wherein X[⊖] is an anion of a mineral acid, for example in the presence of copper or of a copper-I salt, for example a halide or cyanide. An anion of a mineral acid is for example the anion of a hydrohalic acid. In the case of the introduction of R as fluorine, X[⊖] is a fluoride or tetrafluoroborate anion. The heating of a compound of the formula VI where X is a fluoride or tetrafluoroborate anion is performed in hydrofluoric acid or in tetrafluoroboric acid. With the introduction of a cyano group, the diazonium salt of the formula VI is for example reacted as a complex with potassium cyanide in solution. For example, a diazonium salt of the formula VI is

45 reacted with a mixture of potassium cyanide and copper-I sulfate. The liberating of the diazonium salt is effected thermally at temperatures of between 30 and 150°C, preferably between 30 and 40°C when a diazonium fluoride is present, and between 100 and 150°C when a diazonium tetrafluoroborate is present.


45

50 The diazotisation of aromatic amines is performed for example with an alkali metal nitrite, such as sodium nitrite, preferably with the aid of anhydrous sodium nitrite. Diazotisation is performed for example at a temperature of between -10 and +10°C, preferably at a temperature of between 0 and +5°C. By reaction with a mineral acid, there are obtained compounds of the formula VI wherein X is an anion of a mineral acid.

55

60 According to a further process, compounds of the formula I wherein R is a halogen atom can be produced by halogenating compounds of the formula VII

60




Halogenation can be performed on the one hand by the use of halogen, preferably in the presence of a Lewis acid, for example in the presence of an iron-III, aluminium, antimony-III or tin-IV halide; and on the other hand by means of a halogen carrier, for example in the presence of a heavy metal, such as iron, or with the use of a halogenating agent, for example hydrogen chloride, in the presence of an oxidising agent, for example hydrogen peroxide, or of an alkali metal chlorate, for example sodium chlorate, of a nitrosyl halide, for example nitrosyl chloride or bromide, or of an N-halo-imide, for example bromosuccinimide or -phthalimide.

The direct introduction of an iodine atom is performed, with the use of hydrogen iodide, in the presence of an oxidising agent, for example in the presence of nitric acid or mercury oxide.

The halogenation reactions mentioned are performed, depending on the halogen atom concerned, at temperatures of between -10°C and the reflux temperature of the reaction mixture, preferably at a temperature of between -5° and $+30^{\circ}\text{C}$.

Compounds of the formula I in which R is a free hydroxyl group or an amino group can also be obtained by solvolysing or hydrogenolysing a compound of the formula VIII.



wherein R' is a readily solvolysable or hydrogenolysable ether group or acyloxy group, or amino group protected by a protective group.

An ether or acyloxy group which can be readily solvolysed or hydrogenolysed is for example an ether or acyloxy group which is detachable by solvolysis, including hydrolysis, acidolysis or alcoholysis, or by means of reduction, including hydrogenolysis.

An acyloxy group detachable by solvolysis is for example an acyloxy group in which the acyl moiety is the radical of an organic carboxylic acid, for example lower alkanoyl, such as acetyl, halo-lower-alkanoyl, such as haloacetyl, for example chloroacetyl, or carbamoyl, or aroyl, such as benzoyl, also the acyl moiety is the radical of a semi-ester of carbonic acid, such as lower-alkoxy-carbonyl, for example methoxycarbonyl, ethoxycarbonyl or tert-butyloxycarbonyl, 2-halo-lower-alkoxycarbonyl, for example 2,2,2-trichloroethoxycarbonyl or 2-iodoethoxy-carbonyl, unsubstituted or substituted 1-phenyl-lower-alkoxycarbonyl, for example benzyloxycarbonyl or diphenylmethoxycarbonyl or aroylmethoxycarbonyl, for example phenacyloxycarbonyl, also an unsubstituted or substituted 1-polyphenyl-lower-alkyl group, wherein substituents of the phenyl moiety can be for example lower alkyl or lower alkoxy, such as methyl or methoxy, and in particular trityl, or an organosilyl radical, especially trimethylsilyl.

An ether group which is detachable by solvolysis is for example lower alkoxy, for example methoxy or ethoxy or a 1-phenyl-lower-alkoxy group, such as benzyloxy. These radicals can be substituted by lower alkoxy, for example methoxy or ethoxy, or lower alkoxyethoxy, for example methoxyethoxy.

Benzyloxy radicals as detachable ether groups can be unsubstituted or substituted by one or more substituents, for example lower alkyl, such as methyl, ethyl, isopropyl or n-propyl, halogen, for example chlorine or bromine, or lower alkoxy, for example methoxy or ethoxy. These substituents are situated preferably in the ortho position or in the para-position.

Likewise detachable by solvolysis, particularly by hydrolysis or alcoholysis, in an acid medium are aliphatic ether groups substituted for their part in the α -position by an ether group, such as ethoxymethoxy, butoxymethoxy or 1-ethoxyethoxy, and particularly analogous cyclic radicals, for example 1-oxacycloalkan-2-yloxy groups, especially tetrahydropyran-2-yloxy, also for example 4-methoxytetrahydropyran-4-yloxy.

When the solvolysis of the ether or acyloxy groups is performed by hydrolysis, this is carried out, depending on the nature of the detachable groups, in the presence of an organic acid, such as p-toluenesulfonic acid, or a mineral acid, such as hydrochloric acid or sulfuric acid, or in the presence of an alkali metal- or alkaline-earth metal-hydroxide or -carbonate, or in the presence of ammonia or of an amine, such as isopropylamine, or hydrazine hydrate. If solvolysis is performed by means of one of the above-mentioned acids in an alcohol, for example by means

of p-toluenesulfonic acid in ethyl alcohol, solvolysis is performed by alcoholysis.

Ether groups, for example lower alkoxy groups, in particular methoxy or ethoxy, can be detached in solution or in the melt by means of a metal halide, such as aluminium halide or boron halide, for example aluminium trichloride, aluminium tribromide, boron trichloride or boron tribromide. Suitable solvents are for example benzene, nitrobenzene or ethylene chloride (cp. Jour. Chem. Soc. (1961), 1008; Ber. (1943), 76B, 900; Jour. Org. Chem. (1962), 27, 2037; Ber. (1960), 93, 2761; Jour. Am. Chem. Soc. (1968), 24, 2289; and Tetr. Lett. (1966), 4155).

Acyloxy groups detachable by acidolysis are those in which the acyl moiety is an acid radical of semi-esters of carbonic acid, for example tert-lower-alkoxycarbonyl or unsubstituted or substituted diphenylmethoxycarbonyl. Also ether groups, for example tert-lower alkoxy groups, can be detached by acidolysis. Detachment by acidolysis can be performed by treatment with suitable strong organic carboxylic acids, such as lower-alkanecarboxylic acids unsubstituted or substituted by halogen, especially by fluorine, particularly trifluoroacetic acid (if necessary in the presence of an activating agent, such as anisole), as well as with formic acid. Where no prior mention is made, the above reactions are performed in the presence of a solvent or solvent mixture, suitable reactants also being able to act as such.

An ether group detachable by reduction, especially by hydrogenolysis, is in particular an α -aryl-lower-alkyl group, such as an unsubstituted or substituted 1-phenyl-lower-alkyl group, wherein lower alkyl has up to 7 carbon atoms, and wherein substituents, especially of the phenyl moiety, can be for example lower alkyl or lower alkoxy having in each case up to 7 carbon atoms, for example methyl or methoxy, and more especially however benzyl.

The reduction detachment of the ether groups can be performed in particular for example by treatment with catalytically activated hydrogen, such as hydrogen in the presence of a suitable hydrogenating catalyst, for example a nickel, platinum or palladium catalyst, and also a rhodium or ruthenium catalyst; or the process is performed with a hydride-reducing agent, for example lithium aluminium hydride.

By acyloxy radicals detachable by hydrogenolysis are meant those groups which are detached by treatment with a chemical reducing agent (especially with a reducing metal or a reducing metal compound). Such radicals are in particular 2-halo-lower-alkoxycarbonyloxy, such as 2,2,2-trichloroethoxycarbonyloxy, which are detached for example with a reducing heavy metal, for example zinc, or with a reducing heavy metal salt, such as a chromium (II) salt, for example chromium(II) chloride or -acetate, usually in the presence of an organic carboxylic acid, such as formic acid or acetic acid.

The above reduction reactions are performed in a manner known per se, usually in the presence of an inert solvent and, if necessary, with cooling or heating, for example in a temperature range of about -20°C to about 150°C , and/or in a closed vessel under pressure.

Depending on the ether or acyloxy group present, there is preferably selected the most mild of the described solvolysis or hydrogenolysis methods, in order to avoid changes in the pyridazine structure.


A group protecting the amino radical, or an amino protective group, is in particular an acyl group, such as an acyl of an aliphatic, aromatic or araliphatic carboxylic acid, especially lower alkanoyl, for example acetyl or propionyl, or aroyl, for example benzoyl, or acyl of formic acid or of a carbonic acid semi-derivative, for example of a carbonic acid semi-ester, such as formyl, lower alkoxy-carbonyl, for example ethoxycarbonyl or tert-butyloxy-carbonyl, or aryl-lower-alkoxycarbonyl, for example benzyl-oxy-carbonyl.

The detachment of an acyl radical used as an amino protective group can be performed in a manner known per se, for example by solvolysis, particularly by means of alcoholysis, also by means of hydrolysis. The detaching of an acyl radical by alcoholysis can be carried out for example in the presence of a strong basic agent, at elevated temperature, for example at about 50°C to about 120°C . There is used in particular a lower alkanol, for example n-butanol or ethanol, and as a strong base an alkali metal lower alkanolate, for example a sodium or potassium lower alkanolate, for example -n-butyrate or -ethylate, or an alkali metal hydroxide, for example sodium or potassium hydroxide.

Amino protective groups, for example lower-alkoxy-carbonyl groups, such as tert-butyloxy-carbonyl, can be detached particularly gently by acidolysis, for example by treatment with trifluoroacetic acid. A further amino protective group which can be especially mildly detached is an ethoxycarbonyl group which carries in the β -position a silyl group substituted by three hydrocarbon radicals, such as a triphenylsilyl, dimethylbutyl-silyl or in particular trimethylsilyl group. A β -(trimethylsilyl)-ethoxycarbonyl group of this kind forms with the amino group to be protected a corresponding β -trimethylsilylethoxy-carbonylamino group, which can be detached, under mild conditions, by reaction with fluoride ions. Reagents releasing fluoride ions are for example fluorides of quaternary organic bases, such as tetraethylammonium fluoride.

It is to be ensured that only those amino protective groups are used which can be detached selectively with retention of the desired structure of the compounds of the general formula I.

A compound of the formula I in which R is an amino group can be obtained also by selectively reducing in a compound of the formula IX



the nitro group to the amino group. Reduction is preferably performed catalytically, for example in the presence of a noble metal catalyst, such as platinum or palladium on charcoal, by means of hydrogen. Reduction can however be carried out using the methods described in the foregoing, for example with tin and hydrochloric acid, or tin(II)-chloride, the catalytic method mentioned above being however preferred. 15

Within the limits of the definition of the final products, substituents can be introduced, modified or detached in the compounds of the formula I obtained.


For example, resulting compounds of the formula I wherein R is a free amino group can be converted, by means of an acylating agent, for example an acetyl halide or an acetic anhydride, into compounds of the formula I wherein R is an acetamino group. Acylation is preferably carried out in the presence of an organic base, for example in the presence of pyridine, or of a tertiary alkylamine, such as triethylamine or N-ethyldiisopropylamine. 20

Furthermore, resulting compounds of the formula I in which R is a hydroxyl group can be converted, in a manner known per se, by transesterification or by etherification, into compounds of the formula I wherein R is a halogen atom or a methoxy group. 25

The methods described can be performed, in a customary manner, at room temperature, with cooling or heating, under normal or elevated pressure and, if necessary, in the presence or absence of a diluent, catalyst or condensation agent. The reactions can, if required, also be carried out in an inert-gas atmosphere, for example in that of nitrogen. 30

The starting materials are known, or, where they are new, can be produced by methods known per se. In cases in which it appeared to be of advantage, the employed starting products have already been defined after the description of the process.

Ketocarboxylic acids of the formula II can be produced using methods known per se, in the case of example of compounds of the formula II in which R is a halogen atom or a cyano group by halogenation or introduction of a cyano group in a compound of the formula X 35



by the above-described methods, which are carried out in an analogous manner.

Compounds of the general formula III are known, or they can be obtained, using the method described by J.D. Albright et al., J. Het. Chem. 15, 881 (1978), from the corresponding ketocarboxylic acid by reaction with hydrazine. It is also possible to obtain in an analogous manner the starting compounds of the general formula IV from the corresponding aminoketocarboxylic acids. Also the starting compounds of the general formula V are known, and can be obtained for example from the corresponding dihydroxydiethyl ethers by esterification with an acid, for example a hydrohalic acid. Diethyl ether derivatives of the formula V can also be obtained from correspondingly substituted alcohols of the formula OH-CH₂-CH₂-X by etherification. 50

The starting compound of the formula VI and the production thereof are described for example in the German Offenlegungsschrift No. 2,207,517. 55

Compounds of the general formulae VIII and IX can be obtained, using the method described in the first process, from the corresponding ketocarboxylic acids by reaction with hydrazine.

The invention also relates to those embodiments of a process in which a process is discontinued at any stage, or in which a compound obtainable as an intermediate at any stage is used as the starting material and the uncompleted stages are carried out, or in which a starting material is formed under the reaction conditions or, if required, is used in the form of a salt. The invention also includes intermediates resulting therefrom. 60

Also embraced by the invention are therapeutic compositions consisting of an antithrombotically active proportion of a compound of the formula I together with a pharmacologically acceptable solid carrier or liquid diluent. 65

A resulting compound of the formula I wherein R is an amino group can, if desired, be converted into an acid addition salt in a manner known per se. There are used for producing acid addition salts in particular those acids which are suitable for the formation of therapeutically applicable salts. The following may be mentioned as examples of suitable acids:

- 5 hydrohalic acids, sulfuric acids, phosphoric acids, nitric acid, perchloric acid, aliphatic, alicyclic aromatic or heterocyclic carboxylic or sulfonic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid or pyruvic acid; phenylacetic acid, benzoic acid, p-aminobenzoic acid, anthranilic acid, p-hydroxybenzoic acid, salicylic acid or p-amino-salicylic acid, embonic acid, methanesulfonic acid, ethanesulfonic acid, hydroxyethanesulfonic acid or ethylenesulfonic acid; halobenzenesulfonic acid, toluenesulfonic acid, naphthalenesulfonic acid or sulfanilic acid; and methionine, tryptophane, lysine or arginine. 10

Depending on the process conditions, the compound of the formula I wherein R is an amino group can occur also as an acid addition salt.

- 15 The acid addition salts of the novel compounds can be converted, in a manner known per se, into the free compound, for example with basic agents, such as alkalis or ion exchangers. On the other hand, the free bases obtained can form salts with organic or inorganic acids. 15

- The pharmaceutical preparations according to the invention contain at least one compound of the formula I as active ingredient, together with a customary pharmaceutical carrier. The nature of the carriers used is governed largely by the field of application. The pharmaceutical compositions according to the invention, which contain compounds of the formula I as active ingredients, can be administered orally, parenterally or rectally. 20

- Suitable for oral treatment of thrombosis are in particular solid dosage units, such as tablets, dragées and capsules, which preferably contain between 10 and 90% of an active substance of the general formula I in order to render possible the administration of daily doses of between 1.0 and 1000 mg/kg, preferably between 2 and 100 mg/kg, particularly between 5 and 10 mg/kg, to warm-blooded animals having a body weight of about 70 kg. Tablets and dragée cores are produced by combining the compounds of the formula I with solid pulverulent carriers, such as lactose, saccharose, sorbitol, maize starch, potato starch or amylopectin, cellulose derivatives or gelatine, preferably with the addition of lubricants, such as magnesium or calcium stearate, or polyethylene glycols of suitable molecular weight. Dragée cores are subsequently coated for example with concentrated sugar solutions which can also contain for example gum arabic, talcum and/or titanium dioxide, or with a lacquer dissolved in readily volatile organic solvents or solvent mixtures. Colouring agents may be added to these coatings, for example for identification of the various dosage amounts. Soft gelatine capsules and other closed capsules consist for example of a mixture of gelatine and glycerin, and can contain for example mixtures of a compound of the formula I with polyethylene glycol. Hard gelatine capsules contain for example granulates of an active substance with solid pulverulent carriers, such as lactose, saccharose, sorbitol or mannitol; starches, such as potato starch, maize starch or amylopectin, cellulose derivatives as well as magnesium stearate or stearic acid. 30 35 40

- Suitable dosage units for rectal administration are for example suppositories which consist of a combination of an active substance with a suppository foundation substance based on natural or synthetic triglycerides (for example cocoa butter), polyethylene glycols or suitable higher fatty alcohols; and gelatine rectal capsules which contain a combination of the active substance with polyethylene glycols. 45

For liquids to be taken orally, such as syrups and elixirs, the concentration of active substance is chosen to ensure that a single dose can be easily measured out, for example as the content of a tea-spoon or of a measuring spoon, for example 5 ml, or as a multiple of these amounts.

- 50 The following Examples a) to e) are intended to illustrate some typical forms of application, but in no way do they represent the only embodiment thereof. 50

- a) 100.0 g of active substance are mixed with 610.0 g of lactose and 442.0 g of starch; the mixture is then moistened with an alcoholic solution of 8 g of gelatine, and is granulated through a sieve. The granulate is dried, and 60.0 g of talcum, 10.0 g of magnesium stearate and 20.0 g of colloidal silicon dioxide are mixed in; and the mixture is subsequently pressed to form 10,000 tablets, each weighing 125 mg and each containing 10 mg of active substance. The tablets can, if desired, be provided with grooves for a more precise adjustment of the dosage amount. 55

- b) A granulate is prepared from 100.0 g of active substance, 379 g of lactose and the alcoholic solution of 6.0 g of gelatine; after drying, the granulate is mixed with 10.0 g of colloidal silicon dioxide, 40.0 g of talcum, 60.0 g of potato starch and 5.0 g of magnesium stearate, and the mixture is pressed out to form 10,000 dragée cores. These are subsequently coated with a concentrated syrup prepared from 533.5 g of crystallised saccharose, 20.0 g of shellac, 75.0 g of gum arabic, 250.0 g of talcum, 20.0 g of colloidal silicon dioxide and 1.5 g of colouring agent, and finally dried. The dragées obtained each weigh 150 mg and each 65

contain 10 mg of active substance.

c) 10.0 g of active substance and 1990 g of finely ground suppository foundation substance (for example cocoa butter) are thoroughly mixed and then melted. The melt is maintained homogeneous by stirring whilst 1000 2.0 g suppositories each containing 25 mg of active

5 substance are being poured. 5
d) To prepare a syrup having a content of active substance of 0.25%, there are dissolved in 3 litres of distilled water 1.5 litres of glycerin, 42 g of p-hydroxybenzoic acid methyl ester, 18 g of p-hydroxybenzoic acid-n-propyl ester and, with slight warming, 25.0 g of active substance, to this solution are then added 4 litres of 70% sorbitol solution, 1000 g of crystallised saccharose, 10
10 350 g of glucose and an aroma substance, for example 250 g of "Orange Peel Soluble Fluid", 10
Eli Lilly and Co., Indianapolis, or 5 g of natural lemon aroma and 5 g of "half and half" essence, both from Haarmann and Reimer, Holzminden, Germany; the solution obtained is filtered, and the filtrate is subsequently made up with distilled water to 10 litres.

e) To prepare a drip solution containing 1.5% of active substance, 150.0 g of active substance 15
and 30 g of sodium cyclamate are dissolved in a mixture of 4 litres of ethanol (96%) and 1 litre of propylene glycol. A mixture of 3.5 litres of 70% sorbitol solution and 1 litre of water is prepared separately and is then added to the above solution of active substance. An aroma substance, for example 5 g of cough-sweet aroma or 30 g of grapefruit essence, both from Haarmann and Reimer, Holzminden, Germany, is added; the whole is well mixed, filtered, and 20
20 made up with distilled water to 10 litres. 20

The Examples which follow further illustrate the production of the novel compounds of the formula I, but in no way do they limit the scope of the invention. The temperature values are in degrees Centigrade.

25 *Example 1:* 2 g of hydrazine hydrate are added dropwise, with stirring, to a solution of 10 g of 3-chloro-4-morpholino-benzoylpropionic acid in 120 ml of ethanol. The reaction mixture is refluxed for 2 hours, then cooled to room temperature and subsequently filtered under suction. The suction-filter residue is afterwards washed with ethanol and dried at 60° under high vacuum. The yield is 9.2 g of 6-(4-morpholino-3-chlorophenyl)-4,5-dihydro-3(2H)-pyridazinone, 30
30 m.p. 187–189°C. 30

Example 2: The solution of 0.65 g of sodium chlorate in 0.75 ml of water is added dropwise at –5°C, with stirring, to a solution of 3.7 g of 6-(4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone in 5.7 ml of glacial acetic acid and 7.5 ml of concentrated hydrochloric acid. The 35
35 reaction mixture is further stirred for 30 minutes at 0°C, then for 30 minutes at room temperature, and is afterwards poured into 100 ml of ice-water. The pH-value of the suspension formed is adjusted to 6 with concentrated sodium hydroxide solution, and the suspension is subsequently extracted with chloroform; the chloroform extracts are washed with water, dried over sodium sulfate and recrystallised from ethanol to thus obtain 6-(4-morpholino-3-chlorophenyl)-4,5-dihydro-3(2H)-pyridazinone, m.p. 184–186°C. 40
40 40

Example 3: 1.5 g of 6-(3,4-dichlorophenyl)-4,5-dihydro-3(2H)-pyridazinone together with 1.6 ml of morpholine are refluxed for 20 hours, and, after cooling, the reaction mixture is distributed between ethyl acetate and 2 N hydrochloric acid. The organic phases are extracted with 5 N 45
45 hydrochloric acid, and from these 5 N hydrochloric acid extracts is obtained, after adjustment with concentrated sodium hydroxide solution to give a basic reaction, extracting back with ethyl acetate, washing with water and with brine, drying and concentration of these ethyl acetate extracts by evaporation, crystalline 6-(4-morpholino-3-chlorophenyl)-4,5-dihydro-3(2H)-pyridazinone, which has a melting point of 184–186° after recrystallisation from ethanol. 50
50 50

Example 4: The solution of 0.3 ml of bromine in 4.5 ml of chloroform is added at 0°C, with stirring, to a solution of 1.5 g of 6-(4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone in 11 ml of chloroform. The reaction solution is further stirred for 30 minutes at 0°C and for 60 minutes at room temperature; and is then shaken, in a separating funnel, with 1 N sodium 55
55 bicarbonate solution until two clear phases are formed. The organic phase is washed with water, dried over sodium sulfate and concentrated by evaporation. The yield is 1.9 g of crude 6-(4-morpholino-3-bromophenyl)-4,5-dihydro-3(2H)-pyridazinone. For further purification, this is dissolved, with the addition of a small amount of methylene chloride, in 100 ml of ethyl acetate. The solution is washed three times with 2 N hydrochloric acid, and is then extracted with 5 N 60
60 hydrochloric acid. There are then obtained from these extracts, after adjustment with sodium hydroxide solution to give a basic reaction, extraction with ethyl acetate/methylene chloride, washing, drying and concentration of the organic phases by evaporation, 1.3 g of purified produce which, after recrystallisation from ethanol, melts at 175–176°C. 60

65 *Example 5:* 170 g of 3-chloro-4-morpholino-benzoyl-propionic acid-morpholineamide together 65
65 65

with 68 ml of hydrazine hydrate in 2.5 litres of 50% acetic acid are refluxed for 2 hours, and subsequently stirred at room temperature for 16 hours. The product which has precipitated is filtered off with suction, washed with water, and dried at 80°C under high vacuum. The yield is 126 g of crystalline 6-(3-chloro-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone. This is dissolved in 750 ml of dimethylformamide with heating; the solution is then cooled and aqueous ethanol (50%) is added; the product is afterwards filtered off with suction and dried at 60°C under high vacuum, m.p. 185–189°C.

The 3-chloro-4-morpholino-benzoylpropionic acid-morpholineamide required as starting material is produced as follows:

- 200g of 3,4-dichloro-benzoyl-propionic acid together with 350 ml of morpholine are refluxed for 24 hours. The reaction mixture is cooled, and then distributed between ethyl acetate and 2 N hydrochloric acid. The ethyl acetate phases are extracted 6 times with 500 ml of 5 N hydrochloric acid. The combined hydrochloric acid extracts are adjusted with concentrated sodium hydroxide solution to pH 5–6, and the crystals which precipitate are filtered off with suction, and dried at 50°C under high vacuum. The yield is 198 g of 3-chloro-4-morpholino-benzoyl-propionic acid-morpholineamide having a melting point of 94–102°C. The melting point rises to 103–106°C after recrystallisation from ethyl acetate/petroleum ether.

- Example 6:* 9 ml of water and 9 ml of concentrated hydrochloric acid are added to 1 g of 6-(3-amino-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone, and the mixture is diazotised at 0–5°C with a solution of 0.29 g of sodium nitrite in 1 ml of water. After 15 minutes, unreacted nitrite in the solution is decomposed by the addition of urea, and to the reaction mixture is added a solution of 1.8 g of copper(I) chloride in 9 ml of water and 9 ml of concentrated hydrochloric acid. The reaction temperature is then raised from 0–5° to 25°C, and is maintained there for 3 hours with stirring. The reaction mixture is further stirred for 2 hours at 40°C, it is afterwards rendered slightly alkaline with a pH-value of 10; ethyl acetate is subsequently added, and the reaction mixture is filtered through Hyflo (Registered Trade Mark). The organic phase is separated, and the aqueous phase of the filtrate is extracted twice with ethyl acetate. All the collected organic phases are combined, dried over sodium sulfate and concentrated by evaporation. The 6-(4-morpholino-3-chlorophenyl)-4,5-dihydro-3(2H)-pyridazinone obtained as residue crystallises spontaneously with a melting point of 188–192°C.

The 6-(3-amino-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone, used as starting material is obtained as follows:

- 90 g of 6-(4-morpholino-3-nitrophenyl)-4,5-dihydro-3(2H)-pyridazinone (J. Het. Chem. 15, 881 (1978)) are hydrogenated in 2.7 litres of ethanol with 9 g of a 5% palladium on charcoal catalyst at room temperature under normal pressure. The reaction mixture is filtered, and the ethanol filtrate is concentrated by evaporation. The catalyst is suspended in 1 N hydrochloric acid, filtered off, and then washed with 1 N hydrochloric acid. The pH-value of the aqueous phases is adjusted to 6 with concentrated sodium hydroxide solution, and the product which has precipitated is filtered off with suction and washed with water. The product thus obtained is combined with the evaporation residue of the ethanol filtrate, and the whole is dissolved in dimethyl-formamide with heating; the solution is treated with active charcoal and filtered through Hyflo; there is then crystallised out from the filtrate, by cooling and the addition of water, 6-(3-amino-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone, which, after drying at 100°C under high vacuum, melts at 249–253°C.

- Example 7:* 1 g of 6-(3-chloro-4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone together with 1.7 g of 2,2'-dibromo-diethyl ether, 2.5 ml of diisopropylethylamine and 10 ml of dimethylformamide are stirred at 100°C for 18 hours. The reaction mixture is cooled and then distributed between ethyl acetate and 5 N hydrochloric acid. The hydrochloric acid extracts are adjusted to pH 6 with sodium hydroxide solution, and extracted with methylene chloride. The combined organic phases are washed with water, dried over sodium sulfate, and concentrated by evaporation. The yield is 1 g of crude 6-(4-morpholino-3-chlorophenyl)-4,5-dihydro-3(2H)-pyridazinone, which melts at 183–185°C after recrystallisation from ethanol.

- The 6-(3-chloro-4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone required as starting material is produced as follows:

- 4-Acetyl-amino-benzoylpropionic acid, obtained by Friedel-Crafts acylation of acetanilide with succinic anhydride, is converted, in a manner analogous to that described in Example 2, into 3-chloro-4-acetyl-amino-benzoyl-propionic acid. This is converted by hydrolysis in 18% hydrochloric acid into 3-chloro-4-amino-benzoyl-propionic acid (m.p. unpurified 156–158°C). From this is obtained, in a manner analogous to that given in Example 1, by reaction with hydrazine, 6-(3-chloro-4-aminophenyl)-4,5-dihydro-3(2H)-pyridazinone (m.p. unpurified 225–230°C).

- Example 8:* In a manner analogous to that in Example 1, 7 g of 3-fluoro-4-morpholino-benzoylpropionic acid together with 1.32 ml of hydrazine hydrate and 90 ml of ethanol are

refluxed for 2 hours. The reaction mixture is cooled to 0°C; it is further stirred for one hour at this temperature, and the crystals which have precipitated are filtered off with suction and subsequently washed with small amounts of ethanol. The crystals are dried at 50°C under high vacuum to thus obtain 6.25 g of 6-(3-fluorophenyl-4-morpholino)-4,5-dihydro-3(2H)-pyridazinone having a melting point of 167–170°C.

The 3-fluoro-4-morpholino-benzoylpropionic acid used as starting material is produced as follows:

33g of 3,4-difluoro-benzoylpropionic acid (obtained by Friedel-Crafts acylation of 1,2-difluorobenzene with succinic anhydride in the presence of aluminium chloride) together with 60 ml of morpholine are heated at 150°C for 20 hours with stirring. The reaction mixture is cooled, dissolved in ethylacetate, and this solution is washed with 2 N hydrochloric acid and extracted with 5 N hydrochloric acid. The pH-value of the 5 N hydrochloric acid extracts is brought to 6 with concentrated sodium hydroxide solution, and the suspension formed is extracted with ethyl acetate. The organic phases are washed with water, dried over sodium sulfate and concentrated by evaporation. The crystalline residue (31.7 g) together with 18 g of potassium hydroxide, 180 ml of water and 180 ml of ethanol is refluxed for 10 hours; it is then cooled, concentrated by evaporation and distributed between water and ethyl acetate. The pH-value of the aqueous phases is adjusted to 5, and the 3-fluoro-4-morpholino-benzoyl-propionic acid which has precipitated is filtered off under suction and dried (m.p. 164–168°C).

Example 9: 5.8 g of 4-morpholino-3-trifluoromethyl-benzoylpropionic acid-morpholineamide together with 2.2 ml of hydrazine hydrate and 90 ml of 50% acetic acid are refluxed for 1 hour. The reaction mixture is cooled, concentrated in a rotary evaporator, and a small amount of water is added; the pH-value is adjusted to 6 with a 2 N sodium carbonate solution, and the mixture is extracted with methylene chloride. The methylene chloride extracts are washed with water, dried over sodium sulfate and concentrated by evaporation. From the residue is obtained, by recrystallisation from ethanol/petroleum ether, 6-(3-trifluoromethyl-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone, m.p. 163–166°C.

The 4-morpholino-3-trifluoromethyl-benzoylpropionic acid-morpholineamide required as starting material is produced as follows:

12.3 g of o-(4-chloro-3-trifluoromethyl-phenyl)-4-morpholino-acetonitrile (J. Het. Chem. 15, 883 (1978)) are dissolved in 150 ml of tetrahydrofuran, and at 5°C are added, with stirring, 5 ml of 30% ethanolic potassium hydroxide solution. The reaction mixture is stirred for a further 15 minutes at 5°C, and there is then added dropwise, under the same conditions, the solution of 5.9 g of ethyl acrylate in 100 ml of tetrahydrofuran. The reaction mixture is further stirred for 1 hour at room temperature, and subsequently concentrated in a rotary evaporator. To the residue obtained is added toluene three times, and this is again evaporated off in the rotary evaporator. The residue thus obtained is taken up in ether and filtered until clear. The filtrate is concentrated by evaporation to yield 14.3 g of crude γ -cyano- γ -(4-chloro-3-trifluoro-methyl-phenyl)- γ -(4-morpholino)-ethyl butyrate, which is saponified in two stages as follows:

12.3 g of γ -cyano- γ -(4-chloro-3-trifluoromethyl-phenyl)- γ -(4-morpholino)-ethyl butyrate together with 75 ml of acetic acid and 32 ml of water are heated for 2 hours at 100°C. The reaction mixture is concentrated in a rotary evaporator, and the residue is dissolved in 250 ml of ethanol and 9.2 ml of water. The reaction mixture is rendered alkaline with solid potassium hydroxide; a further 1.9 g of solid potassium hydroxide are added, and stirring is maintained for 30 minutes whilst the reaction mixture is being refluxed, and subsequently for 16 hours at room temperature.

The reaction mixture is concentrated by evaporation, and the residue is distributed between ethyl acetate and water; the aqueous phases are then rendered acidic with concentrated hydrochloric acid, and extracted with ethyl acetate. From this extract are obtained, after concentration by evaporation, 6.2 g of 4-chloro-3-trifluoromethyl-benzoylpropionic acid having a melting point of 87–96°C. The unpurified material is directly used further as follows:

3 g of 4-chloro-3-trifluoromethyl-benzoylpropionic acid together with 6.5 ml of morpholine are refluxed for 20 hours. The reaction mixture is cooled, taken up in ethyl acetate, washed with 1 N hydrochloric acid and water, dried over sodium sulfate and concentrated by evaporation. There are obtained as residue 3.2 g of unpurified 4-morpholino-3-trifluoromethyl-benzoylpropionic acid-morpholineamide, which can be further used directly. Crystals having a melting point of 76–79°C are obtained after recrystallisation from a mixture of ether and petroleum ether.

Example 10: The solution of 3.5 ml of acetic anhydride in 30 ml of dimethylformamide is added dropwise to a suspension of 10 g of 6-(3-amino-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone (obtained according to Example 6), 6.2 ml of diisopropylethylamine and 120 ml of dimethylformamide. The reaction mixture is further stirred for 48 hours at room temperature, and then concentrated in a rotary evaporator. The residue is distributed between ethyl acetate and 2 N hydrochloric acid. The hydrochloric acid extracts are combined, and rendered basic

with concentrated sodium hydroxide solution. The product which precipitates is filtered off with suction, washed with water and dried under high vacuum. The yield after recrystallisation from dimethylformamide/ethanol and purification through active charcoal is 7.5 g of 6-(3-acetamino-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone having a melting point of 240–242°C.

Example 11: 2.2 g of 6-(4-amino-3-methyl-phenyl)-4,5-dihydro-3(2H)-pyridazinone together with 5.5 ml of diisopropylethylamine, 3.7 g of dibromodiethyl ether and 11 ml of dimethylformamide are stirred at 100°C for 6 hours. The reaction mixture is cooled to room temperature, and ethyl acetate is added. The diisopropylamine hydrobromide which has precipitated is filtered off with suction, and washed with ethyl acetate. The combined filtrates are washed with water, dried over sodium sulfate and concentrated by evaporation. The residue is chromatographed through silica gel. After separation of non-polar impurities with a mixture of toluene:ethyl acetate = 1:1, the 6-(4-morpholino-3-methyl-phenyl)-4,5-dihydro-3(2H)-pyridazinone is eluted with ethyl acetate, and melts at 208–211°C after recrystallisation from a mixture of methylene chloride/petroleum ether.

The 6-(4-amino-3-methyl-phenyl)-4,5-dihydro-3(2H)-pyridazinone required as starting material is produced as follows:


There are obtained from 70g of N-acetyl-1,2-toluidine, with 47 g of succinic anhydride and 234 g of aluminium chloride in 2000 ml of tetrachloroethane, by the customary method, 50 g of 3-(3-methyl-4-acetamido-benzoyl)-propionic acid, m.p. 150–160°C, as crude product. From this are obtained, by hydrolysis in 18% hydrochloric acid, 28 g of crude 3-(4-amino-3-methyl-benzoyl)-propionic acid. And from 6 g of 3-(4-amino-3-methyl-benzoyl)-propionic acid are obtained, with 1.7 ml of hydrazine hydrate in 70 ml of ethanol, in a manner analogous to that in Example 1, 2.6 g of 6-(4-amino-3-methyl-phenyl)-4,5-dihydro-3(2H)-pyridazinone having a melting point of 215–225°C.

Example 12: 25 g of 3-amino-4-morpholino-benzoylpropionic acid are dissolved in 24.2 g of concentrated hydrochloric acid and 70 ml of water, and the solution is diazotised at 0°C with a solution of 7.7 g of sodium nitrite in 40 ml of water. A reagent (produced by mixing a solution of 27 g of potassium cyanide in 50 ml of water with the solution, heated to 60°C, of 24.2 g of copper sulfate pentahydrate in 95 ml of water) is cooled to room temperature, and is added to the diazonium solution at 0–5°C. The reaction mixture is afterwards stirring for 16 hours at room temperature; it is then diluted with water, adjusted to pH 14 with concentrated sodium hydroxide solution, and washed three times with ethyl acetate. The aqueous phases are purified with active charcoal, adjusted to pH 2 with concentrated hydrochloric acid, and extracted with ethyl acetate. The organic extracts are filtered clear, washed with 2 N hydrochloric acid and with water, dried over sodium sulfate and concentrated by evaporation. The yield is 16 g of crude 3-cyano-4-morpholino-benzoylpropionic acid, which is reacted with hydrazine hydrate in a manner analogous to that in Example 1. There is thus obtained 6-(3-cyano-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone, m.p. 212–214°C, recrystallised from methylene chloride/dimethylformamide.

The 3-amino-4-morpholino-benzoylpropionic acid required as starting material is obtained by reaction of 3-nitro-4-chlorobenzoylpropionic acid with morpholine, analogously to Example 8, and reduction of the formed 3-nitro-4-morpholino-benzoylpropionic acid.


CLAIMS

1. A pyridazinone of the general formula I



wherein R is halogen atom, or the amino, acetamino, methyl, cyano, hydroxyl, methoxy or trifluoromethyl group, the tautomeric forms thereof, and an acid addition salt of a compound in which R is amino.

2. A pyridazinone of the general formula I



5

10 wherein R is a halogen atom or the trifluoromethyl group, and the tautomeric forms thereof. 10

3. A pyridazinone of the general formula I according to Claim 1, wherein R is a chlorine or bromine atom, and the tautomeric forms thereof.

4. 6-(3-Chloro-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone, and the tautomeric forms thereof.

15 5. 6-(3-Amino-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone, the tautomeric forms and acid addition salts thereof. 15

6. 6-(3-Acetylamino-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone, and the tautomeric forms thereof.

20 7. 6-(3-Cyano-4-morpholino-phenyl)-4,5-dihydro-3(2H)-pyridazinone, and the tautomeric forms thereof. 20

8. A pharmaceutical preparation containing a compound of the formula I of Claim 1.

9. A compound of the formula I of Claim 1 for application in a process for the therapeutic treatment of the human or animal body.

10. A compound of the formula I of Claim 1 for use as an antithrombotically effective agent.

25 11. Use of a compound of the formula I of Claim 1 for producing pharmaceutical preparations. 25

12. A pharmaceutical preparation containing any one of the compounds of Claims 2-4.


13. A compound as claimed in any one of Claims 2-4 for application in a process for the therapeutic treatment of the human or animal body.

30 14. A compound as claimed in any one of Claims 2-4 for use as an antithrombotically effective agent. 30

15. Use of a compound as claimed in any one of Claims 2-4 for producing pharmaceutical preparations.

16. A process for producing a compound of the general formula I


35



40

45 wherein R is a halogen atom, or the amino, acetylamino, methyl, cyano, hydroxyl, methoxy or trifluoromethyl group, the tautomeric forms thereof, and an acid addition salt of the compound in which R is amino, which process comprises 45

a) reacting a ketocarboxylic acid of the formula II




50

55

or a reactive derivative of such a ketocarboxylic acid, wherein R has the meaning defined under the formula I, with hydrazine; or


b) reacting a compound of the formula III



5

- 10 wherein R has the meaning defined under the formula I, and Y is a group detachable together with hydrogen, with morpholine; or
c) reacting a compound of the formula IV


10



15

- 20 with a diethyl ether derivative of the formula V


20



25

- 30 wherein X is a group detachable together with hydrogen; or
d) introducing into a compound of the formula VI


30



35

- 40 wherein X⁻ is an anion of a mineral acid, in the presence of copper or of a copper-I salt, a halogen atom or a cyano group as R; or
e) halogenating a compound of the formula VII


40



45

- 50 f) solvolysing or hydrogenolysing a compound of the formula VIII


50



55

- 60 wherein R' is a readily solvolysable or hydrogenolysable ether group or acyloxy group, or amino group protected by a protective group; or
g) selectively reducing in a compound of the formula IX

60



(IX)

5

10 the nitro group to the amino group; and/or, if desired, converting in a resulting compound of the formula I, in which R is an amino group, this group into an acetamino group, and/or, if desired, converting a resulting compound of the formula I in which R is an amino group into an acid addition salt, and/or, if desired, converting a resulting acid addition salt of a compound of the formula I into a compound having a free amino group.

10

15 17. A process as claimed in Claim 16 substantially as hereinbefore described with reference to any one of Examples 1 to 12.

15

18. A compound obtainable by any one of the processes according to Claim 16.

Printed for Her Majesty's Stationery Office by Burgess & Son (Abingdon) Ltd.—1982.
Published at The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.